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Pregabalin may reduce neuropathic pain in
burn victims
CAROLINE NIKOLAIDIS, Wayne State University School of Medicine, fh9700@wayne.edu

ABSTRACT

A clinical decision report using:

Gray P, Kirby J, Smith MT, et al. Pregabalin in severe burn injury pain: a double-blind, randomized placebo-controlled trial. Pain.
2011;152(6):1279-1288. https://doi.org/10.1016/j.pain.2011.01.055
for a patient with burn injury pain.
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Clinical-Social Context
Ms. Anna Grant (pseudonym) is a white woman in her 50s who presented to the Emergency Room of an urban
level 1 trauma center with extensive thermal burns to the arm, forearm, hand, and fingers of a single upper
extremity following contact with hot liquid. Ms. Grant has a past medical history significant for fibromyalgia. She is
retired, resides in a home with family members in a middle-class neighborhood, and states that she has adequate
social and financial support. Evaluation of her burns revealed Total Body Surface Area (TBSA) affected
approximately equal to 5.2%: 4.0% was deep partial thickness, and 1.2% was full thickness. Given the extent of her
injury, her care team recommended surgical debridement and temporary xenograft placement, with future plans
for superficial thickness skin grafting.
Two weeks after her injury, Ms. Grant complained of persistent “burning” and “sharp tingling” in her affected
extremity. She had previously been prescribed 0.5 milligrams of dilaudid once every four hours for pain. However,
she inquired whether a non-opioid medication could be used to control her pain instead. She had experienced side
effects with dilaudid such as lightheadedness and drowsiness. Additionally, she expressed a desire to decrease her
consumption of opioids, as she had witnessed high rates of opioid addiction within her community. She denied a
personal history of opioid use prior to this incident and a familial history of opioid addiction. Her treatment team
wondered whether gabapentinoids, such as gabapentin or pregabalin, could alleviate Ms. Grant’s classic
neuropathic symptoms and lower her requirement for opioid medications. Ms. Grant denied a history of
gabapentionoid use. Pregabalin was chosen for investigation because it displays a favorable pharmacokinetic
profile compared to gabapentin, such as earlier onset of clinical effect, linear absorption pharmacokinetics, and
greater potency.1

Clinical Question
Can pregabalin reduce neuropathic pain and reduce risk of opioid dependency in burn victims?
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Research Article
Gray P, Kirby J, Smith MT, et al. Pregabalin in severe burn injury pain: a double-blind, randomized placebo-controlled trial. Pain.
2011;152(6):1279-1288. https://doi.org/10.1016/j.pain.2011.01.055 1

Description of Related Literature
A PubMed search was performed using the terms “pregabalin” AND “burn”, yielding 21 results. Each article was reviewed with the
goal of identifying a randomized control trial that would address our clinical question.
Of the 21 PubMed results, eight were unrelated to the clinical question and immediately excluded.3-15 One result was a retrospective
cohort study that identified risk factors in developing chronic neuropathic pain following hand burns.16 Three results investigated
pruritis17-19, a subtype of neuropathic pain often experienced by burn victims. Chung et al. is a review that described the physiologic
mechanisms underlying post-burn pruritis17, while Foroutan et al. and Ahuja et al. are reviews that investigated the antipruritic
effects of pregabalin in burn patients.18,19 Both aforementioned studies concluded that pregabalin was effective in reducing postburn pruritis. However, because Ms. Grant was not experiencing post-burn pruritis, these articles were excluded.
Kaul et al. was a retrospective chart review that studied the effects of gabapentinoids in reducing pruritis and other forms of
neuropathic pain in pediatric burn victims.20 The authors found gabapentin and pregabalin to be highly efficacious. However, this
study was ultimately excluded as it was not a randomized controlled trial, and did not address whether pregabalin would reduce
opioid consumption. Additionally, Ms. Grant would not have fit inclusion criteria for this study on the basis of her age.
Wong et al. is another retrospective chart review conducted upon patients experiencing post-burn neuropathic pain.21 69% of
patients who completed the study achieved pain score reduction after three weeks or less of treatment with pregabalin. However,
like Kaul et al., this study was also excluded as it was not a randomized controlled trial and did not address the effect of pregabalin
on patients’ opioid consumption.
The two remaining articles (Jones et al. and Gray et al.) were randomized, double-blind, placebo-controlled studies investigating the
efficacy of pregabalin in reducing neuropathic pain and opioid consumption in burn victims.22,2 Jones et al. was a study conducted on
54 burn patients with a median TBSA affected of 5%.22 Patients were randomized into three treatment groups: pregabalin 300 mg
daily, pregabalin 600 mg daily, and placebo. Post-burn pain levels were measured using the 10-point Visual Analog Scale.
Additionally, opioid consumption was recorded either during the first three days of treatment or until the patient was discharged,
whichever came first. A statistically significant difference in post-burn pain levels was identified between the Pregabalin 300 and
Pregabalin 600 groups. However, the difference in post-burn pain levels between both Pregabalin groups and the placebo group
were statistically insignificant. In addition, the difference in opioid consumption between all three groups was statistically
insignificant. This study had shortcomings, including a high participant attrition rate following discharge from the hospital and
limited data collection following an unanticipated change in the standard of care for burn patients at the investigators’ institution,
leading to shorter hospitalization periods and decreased enrollment.
The second study, Gray et al., was conducted on 90 burn victims with 5% or greater TBSA affected.2 Patients experiencing symptoms
of neuropathic pain were randomized into two treatment arms, pregabalin or placebo. Patients in the pregabalin group received 75
mg of pregabalin twice daily, which could be up-titrated to 300 mg twice daily if pain scores remained high. Unlike Jones et al., postburn pain levels were measured using the Neuropathic Pain Scale (NPS), an assessment tool that quantified participants’ perception
of ten neuropathic pain symptoms. This allowed researchers to quantify how “hot” and “sharp” participants’ pain felt throughout
the study. Gray et al. also studied opioid consumption throughout the 4-week trial.
Gray et al. was ultimately selected for critical appraisal. Compared with Jones et al., Gray et al. possessed larger treatment cohorts
and lower attrition rates. Importantly, unlike Jones et al., Gray et al. utilized the presence of neuropathic pain, such as hot and sharp
pain, as inclusion criteria for patient enrollment. Prior to concluding the literature search, additional searches were performed to
ensure that all articles relevant to the clinical question were previously identified. To do so, a search for “Related Articles” associated
with Gray et al. was performed within Google Scholar, and both Google Scholar and UpToDate were searched using the terms
“pregabalin” and “burn,” yielding no novel results which addressed our clinical question.
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This area of study has Strength of Recommendation Taxonomy (SORT) strength of recommendation B for limited quality, patientoriented evidence.23

Critical Appraisal
Gray et al. is a randomized, double-blind, placebo-controlled study investigating the efficacy of pregabalin in reducing neuropathic
pain and opioid consumption in burn victims. While the authors did not disclose their source of funding, they declared no conflicts of
interest in the design or conduct of the trial. This study qualifies as level of Evidence 1B per SORT criteria. 23
Patients between 18 and 65 years of age who were admitted to the Burn Unit of a large, tertiary referral hospital in Australia were
screened for inclusion in the trial. Immediate exclusion criteria included less than 5% TBSA burned, regular use of antiepileptic drugs
at the time of the burn injury, neuropathic pain prior to burn injury, administration of intravenous lidocaine or mexiletine after burn
injury, allergy to gabapentinoids, and history of psychiatric illness or substance abuse. Patients who were not immediately excluded
were subsequently screened for study entry by completing the NPS every day. If a patient rated either “hot pain” or “sharp pain”
greater than or equal to 4, they were offered entry into the trial given that they were not pregnant and demonstrated a creatinine
clearance greater than or equal to 60 milliliters per minute, liver enzyme levels within normal limits, and an Internationalized
Normalized Ratio less than 1.5. Ultimately, 90 patients were enrolled in the trial. Given her past medical history and the quality of
her neuropathic symptoms, Ms. Grant would have qualified for enrollment. Information regarding the participants’ past medical
histories, including chronic pain conditions, was not provided. Most of the study participants were younger than Ms. Grant (mean
age of 35.7 with S.D. of 12.8), and most were male (83.3%). The mean TBSA burn for participants was not provided. Like Ms. Grant,
75.5% of participants had burns severe enough to warrant skin grafting.
Participants were randomized into two cohorts for the duration of the 28-day trial. 46 participants entered the pregabalin arm, while
44 participants entered into the placebo arm. The staff and researchers were blinded to the group allocation for the duration of the
study. This sample size was sufficient to obtain a significance level of 𝛼=0.05. Initially, patients received 1 capsule (75 mg pregabalin
or placebo) by mouth twice daily. Patients continued on this regimen unless they rated their perception of “sharp pain” or “hot
pain” on their daily NPS greater than or equal to 4. If this occurred, their medication was increased to 150 mg pregabalin or placebo
twice daily. If they rated their perception of “sharp pain” or “hot pain” greater or equal to 4 on any subsequent day, their medication
was increased to the maximum dose of 300 mg pregabalin or placebo twice daily. It should be noted that pain scales including the
NPS do not provide an objective measure of pain, as pain considered mild by one participant might be considered severe to another.
Additionally, patients completed their daily NPS alongside blinded research nurses, who could have introduced observer bias. After
28 days, medications were weaned and stopped. Primary outcome measures included the “sharp pain” and “hot pain” scores on the
NPS. Additional outcomes measured included the remaining elements of the NPS, daily opioid requirement, procedural pain score,
side effect proﬁle, and persistence of pain at a 6-month follow-up. The study attempted to maintain a standardized regimen with
regard to analgesic administration. However, opioids were administered in various routes depending on patients’ individual needs.
As investigators noted, an ideal approach would have been to provide all patients with an intravenous morphine patient-controlled
analgesia device for the duration of the 28-day trial. However, this would have been impractical and increased the risk of
intravenous line infection. Overall, the pregabalin arm had a 73% retention rate while the placebo arm had a 75% retention rate.
Participants in the pregabalin arm demonstrated statistically significant improvements in sharp and hot pain compared to placebo
during the trial (P=0.04 and P=0.01 respectively). Additionally, investigators noted a statistically signiﬁcant improvement in
procedural pain in patients who received pregabalin versus placebo (P=0.02). The average daily Morphine Parenteral Equivalent
(MPE) dose for each 7-day period of the trial showed a statistically significant decrease in opioid requirement within either cohort,
reﬂecting patient recovery. However, differences in opioid consumption between the placebo and pregabalin groups were not
statistically significant (P>0.05). The difference in frequency of side effects between the pregabalin and placebo groups and
persistence of pain 6 months after injury was statistically insignificant.

Clinical Application
Two weeks after sustaining a burn injury, Ms. Grant complained of bothersome sharp and burning sensations in
her affected upper extremity, similar to those experienced by participants in Gray et al. Additionally, Ms. Grant
was hesitant to continue taking opioid medications, citing unpleasant side effects, as well as risk of developing
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opioid addiction, which she previously observed in her community. Gray et al. found pregabalin to be successful in
decreasing symptoms of neuropathic pain similar to ones that Ms. Grant was experiencing. It did not, however,
address the effect of pregabalin in patients with chronic pain syndromes like fibromyalgia, limiting its applicability
to Ms. Grant. Additionally, Gray et al. did not demonstrate a statistically significant decrease opioid consumption
among pregabalin and placebo cohorts. Ms. Grant was informed that pregabalin had demonstrated effectiveness
in reducing the “hot” and “sharp” pain that she was experiencing in her hands, but that data was unclear regarding
its effect on patients’ opioid consumption. Ultimately, Ms. Grant stated that she would be interested in trying
pregabalin in order to combat her neuropathic symptoms, which she found highly uncomfortable.

New Knowledge Related to Clinical Decision Science
Burn pain can be multifactorial in nature and challenging to treat. The emergence of the opioid epidemic in the United States poses
an additional hurdle for physicians treating pain, prompting them to weigh the short-term benefit of improved pain control against
the long-term risk of addiction. Utilizing a personalized, multimodal approach can help providers better control patients’ pain levels
while respecting their psychosocial needs. For example, in the case of Ms. Grant, identifying the presence of neuropathic pain
allowed her treatment team to explore additional pharmacologic measures for pain relief. Additionally, refusal to explore adjunctive
medications would have been insensitive considering her past experiences with opioid addiction in her community. Based on results
from Gray et al., pregabalin may be an enticing treatment option for burn victims experiencing symptoms of neuropathic pain.
However, further data is warranted to demonstrate its ability to lower opioid consumption, as well as its efficacy in patients with
chronic pain syndromes, such as fibromyalgia.

Conflict Of Interest Statement
The author declares no conflicts of interest.

References
1.
2.
3.
4.

5.

6.

7.

8.

4

Toth C. Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf.
2014;5(1):38-56. https://doi.org/10.1177/2042098613505614
Gray P, Kirby J, Smith MT, et al. Pregabalin in severe burn injury pain: a double-blind, randomised placebo-controlled trial. Pain.
2011;152(6):1279-1288. https://doi.org/10.1016/j.pain.2011.01.055
Nicholson GA. SPTLC1-Related Hereditary Sensory Neuropathy. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews®.
September 23, 2002. Seattle (WA): University of Washington, Seattle.
Khazaka M, Laverdière J, Bouchard A, Ferreira V, Mathieu A. Identification of Possible Causative Agents in a Polymedicated
Patient Presenting With Toxic Epidermal Necrolysis [published online ahead of print, 2020 Jun 26]. J Pharm Pract.
2020;897190020934295. https://doi.org/10.1177/0897190020934295
Asghar A, Aamir MN, Sheikh FA, Ahmad N, Alotaibi NF, Bukhari SNA. Preparation, Characterization of Pregabalin and Withania
coagulans Extract-Loaded Topical Gel and Their Comparative Effect on Burn Injury. Gels. 2022;8(7):402.
https://doi.org/10.3390/gels8070402
Barohn RJ, Gajewski B, Pasnoor M, et al. Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life
Situations (PAIN-CONTRoLS): Bayesian Adaptive Comparative Effectiveness Randomized Trial [published correction appears in
JAMA Neurol. 2020 Nov 1;77(11):1453]. JAMA Neurol. 2021;78(1):68-76. https://doi.org/10.1001/jamaneurol.2020.2590
Fowler M, Garza TH, Slater TM, Maani CV, McGhee LL. The relationship between gabapentin and pregabalin and posttraumatic
stress disorder in burned servicemembers. J Burn Care Res. 2012;33(5):612-618.
https://doi.org/10.1097/BCR.0b013e31823dc710
Johannessen Landmark C, Beiske G, Baftiu A, Burns ML, Johannessen SI. Experience from therapeutic drug monitoring and
gender aspects of gabapentin and pregabalin in clinical practice. Seizure. 2015;28:88-91.
https://doi.org/10.1016/j.seizure.2015.02.017

ISSN: 2379-4550
http://digitalcommons.wayne.edu/crp, © 2022 The Author(s)
Licensed under Creative Commons Attribution 4.0 International (CC-BY-4.0)

NIKOLAIDIS C. Pregabalin may reduce neuropathic pain in burn victims. Clin Res Prac. Dec 6
2022;8(2):eP2894. https://doi.org/10.22237/crp/1667261040

9.

10.
11.

12.
13.

14.
15.
16.
17.
18.
19.
20.

21.
22.

23.

5

VOL 8 ISS 2 / eP2894 / DECEMBER 6, 2022
https://doi.org/10.22237/crp/1667261040

Cinotti R, Besnard N, Desmedt L, et al. Feasibility and impact of the implementation of a clinical scale-based sedation-analgesia
protocol in severe burn patients undergoing mechanical ventilation. A before-after bi-center study. Burns. 2020;46(6):13101317. https://doi.org/10.1016/j.burns.2020.02.009
Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy.
Diabetes Metab Res Rev. 2012;28 Suppl 1:8-14. https://doi.org/10.1002/dmrr.2239
Friedlander EB, Soon R, Salcedo J, Davis J, Tschann M, Kaneshiro B. Prophylactic Pregabalin to Decrease Pain During Medication
Abortion: A Randomized Controlled Trial. Obstet Gynecol. 2018;132(3):612-618.
https://doi.org/10.1097/AOG.0000000000002787
Friedlander EB, Raidoo S, Soon R, et al. The experience of pain in real-time during medication abortion. Contraception.
2022;110:71-75. https://doi.org/10.1016/j.contraception.2022.03.003
Baftiu A, Feet SA, Larsson PG, et al. Utilisation and polypharmacy aspects of antiepileptic drugs in elderly versus younger
patients with epilepsy: A pharmacoepidemiological study of CNS-active drugs in Norway, 2004-2015. Epilepsy Res. 2018;139:3542. https://doi.org/10.1016/j.eplepsyres.2017.11.001
Jones DL, Sorkin LS. Systemic gabapentin and S(+)-3-isobutyl-gamma-aminobutyric acid block secondary hyperalgesia. Brain Res.
1998;810(1-2):93-99. https://doi.org/10.1016/s0006-8993(98)00890-7
Jun JH, Yaksh TL. The effect of intrathecal gabapentin and 3-isobutyl gamma-aminobutyric acid on the hyperalgesia observed
after thermal injury in the rat. Anesth Analg. 1998;86(2):348-354. https://doi.org/10.1097/00000539-199802000-00025
Klifto KM, Yesantharao PS, Dellon AL, Hultman CS, Lifchez SD. Chronic Neuropathic Pain Following Hand Burns: Etiology,
Treatment, and Long-Term Outcomes. J Hand Surg Am. 2021;46(1):67.e1-67.e9. https://doi.org/10.1016/j.jhsa.2020.07.001
Chung BY, Kim HB, Jung MJ, et al. Post-Burn Pruritus. Int J Mol Sci. 2020;21(11):3880. Published 2020 May 29.
https://doi.org/10.3390/ijms21113880
Foroutan N, Nikvarz N. Role of Pregabalin in Management of Pruritus: A Literature Review. J Pharm Pharm Sci. 2016;19(4):465474. https://doi.org/10.18433/J35K6N
Ahuja RB, Gupta GK. A four arm, double blind, randomized and placebo controlled study of pregabalin in the management of
post-burn pruritus. Burns. 2013;39(1):24-29. https://doi.org/10.1016/j.burns.2012.09.016
Kaul I, Amin A, Rosenberg M, Rosenberg L, Meyer WJ 3rd. Use of gabapentin and pregabalin for pruritus and neuropathic pain
associated with major burn injury: A retrospective chart review. Burns. 2018;44(2):414-422.
https://doi.org/10.1016/j.burns.2017.07.018
Wong L, Turner L. Treatment of post-burn neuropathic pain: evaluation of pregablin. Burns. 2010;36(6):769-772.
https://doi.org/10.1016/j.burns.2009.05.018
Jones LM, Uribe AA, Coffey R, et al. Pregabalin in the reduction of pain and opioid consumption after burn injuries: A
preliminary, randomized, double-blind, placebo-controlled study. Medicine (Baltimore). 2019;98(18):e15343.
https://doi.org/10.1097/MD.0000000000015343
Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading
evidence in the medical literature. J Am Board Fam Pract. 2004;17(1):59-67. https://doi.org/10.3122/JABFM.17.1.59

ISSN: 2379-4550
http://digitalcommons.wayne.edu/crp, © 2022 The Author(s)
Licensed under Creative Commons Attribution 4.0 International (CC-BY-4.0)

